These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22901187)

  • 1. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
    Zhao X; Wang S; Wu J; Li X; Wang X; Gao Z; Wu W; Wang H; Wang J; Qian J; Ma K; Li H; Han B; Bai C; Li Q; Liu W; Lu D
    PLoS One; 2015; 10(5):e0129232. PubMed ID: 26020272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
    Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
    J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
    Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
    Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
    Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
    Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
    Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J; Leaw SJ; Xu Y; Zheng D
    Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
    Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
    Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM
    Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
    Chen X; Zhang L; Ren S; Li X; Zhou F; Li W; Gao G; He Y; Zhou C
    Med Oncol; 2014 Apr; 31(4):865. PubMed ID: 24535606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
    Brunetto AT; Carden CP; Myerson J; Faria AL; Ashley S; Popat S; O'Brien ME
    J Thorac Oncol; 2010 Sep; 5(9):1397-403. PubMed ID: 20644495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.